Tackling Eosinophilic Disorders

Prefer to attend in person? Register for our live program at ExchangeCME.com/EGPAHESPhillyLive.

Program Overview

Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are both rare types of eosinophilic disorders. Diagnosis and management of these disorders is challenging due to their complex and overlapping pathologic features and heterogeneous systemic involvement. Both disorders carry substantial risks of morbidity and mortality due to delayed diagnosis and inadequate treatment. Interleukin (IL)-5 is a key driver of pathophysiology; therapies targeting IL-5 or the IL-5 receptor are a mainstay of treatment. In this Mechanisms to Medicine symposium, an expert panel will discuss key pathophysiologic mechanisms in EGPA and HES with a focus on clinical implications for diagnosis and treatment.

Target Audience

The educational design of this activity addresses the needs of clinical immunologists/allergists, rheumatologists, pulmonologists, hematologists, and other specialists who identify and manage patients with EGPA or HES.

Educational Objectives 

After completing this activity, the participant should be better able to:

1. Describe the pathophysiologic causes and biopsychosocial burdens of eosinophilic disorders, such as EGPA and HES, including implications for diagnosis and treatment
2. Identify patients with EGPA or HES based on symptomology, red flags, medical history, ancillary testing, and appropriate multidisciplinary collaboration
3. Analyze the clinical rationale and trial evidence for biologic therapies for patients with EGPA or HES
4. Individualize biologic-based treatment regimens for patients with EGPA or HES to reduce corticosteroid dependence, optimize disease control, and target long-term remission

Agenda

6:30 am-6:40 am Preactivity Questionnaire and Faculty Introductions
6:40 am-6:55 am Burdens and Pathophysiology of Eosinophilic Disorders: Focus on EGPA and HES
6:55 am-7:10 am Diagnostic Challenges in HES and EGPA
7:10 am-7:30 am Evolving Management Recommendations for EGPA
7:30 am-7:45 am Evolving Management Recommendations for PDGFRA-negative HES
7:45 am-8:00 am Key Takeaways, Recap, Postactivity Questionnaire, and Q&A Session

Disclosures of Conflicts of Interest

Integritas adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Integritas are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Anisha B. Dua, MD, MPH: Consulting Fees: Amgen, Abbvie, Astra Zeneca, Sanofi, GSK, Novartis; Contracted Research: Amgen Novartis

Flavia Hoyte, MD: Consulting Fees: AstraZeneca plc, Genentech, Sanofi-Aventis U.S. LLC, Teva Pharmaceutical Industries Ltd., GSK; Contracted Research: Institution received research support from Genentech, Inc., Sanofi-Aventis U.S. LLC, GSK plc; Fees for Non-CE Services Received Directly From an Ineligible Entity or Their Agents: AstraZeneca plc, Genentech; Stock Shareholder: Amgen

Michael E. Wechsler, MD, MMSc: Consulting Fees: Allakos, Amgen, Areteia Therapeutics, Arrowhead Pharmaceutical, AstraZeneca, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Eli Lilly, Equillium, Glaxosmithkline, Incyte, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Pharming, Phylaxis, Pulmatrix, Rapt Therapeutics, recludix Pharma, Roche/Genentech, Regeneron, Sanofi/Genzyme, Sentien, Sound Biologics, Tetherex Pharmaceuticals, Uniquity Bio, Upstream Bio, Verona Pharma, Zurabio; Stock Options: Upstream Bio

The planners and managers have no relevant financial relationships with ineligible companies.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Americans With Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc.). Please contact us prior to the live event at info@exchangecme.com.

Integritas Contact Information

For questions about this activity, please contact us at info@exchangecme.com.